GSA Capital Partners LLP acquired a new stake in shares of Bruker Co. (NASDAQ:BRKR) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 6,698 shares of the medical research company’s stock, valued at approximately $266,000.
Other institutional investors have also recently made changes to their positions in the company. Flagship Harbor Advisors LLC lifted its position in Bruker by 109.2% during the second quarter. Flagship Harbor Advisors LLC now owns 1,094 shares of the medical research company’s stock valued at $44,000 after buying an additional 571 shares during the period. Citizens Financial Group Inc RI purchased a new position in shares of Bruker in the 2nd quarter worth about $50,000. Canada Pension Plan Investment Board raised its position in shares of Bruker by 73.8% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,700 shares of the medical research company’s stock worth $69,000 after purchasing an additional 722 shares during the last quarter. Hanseatic Management Services Inc. raised its position in shares of Bruker by 30.9% in the 2nd quarter. Hanseatic Management Services Inc. now owns 2,086 shares of the medical research company’s stock worth $85,000 after purchasing an additional 492 shares during the last quarter. Finally, Macquarie Group Ltd. raised its position in shares of Bruker by 60.4% in the 2nd quarter. Macquarie Group Ltd. now owns 4,576 shares of the medical research company’s stock worth $186,000 after purchasing an additional 1,724 shares during the last quarter. 66.38% of the stock is owned by institutional investors and hedge funds.
Several research firms have recently issued reports on BRKR. TheStreet raised Bruker from a “c+” rating to a “b” rating in a research report on Monday, August 3rd. Citigroup lifted their price target on Bruker from $38.00 to $47.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. SVB Leerink lifted their price target on Bruker from $45.00 to $50.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Wells Fargo & Company lifted their price target on Bruker from $42.00 to $52.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Finally, BidaskClub raised Bruker from a “sell” rating to a “hold” rating in a research report on Thursday, October 29th. Six equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Bruker has a consensus rating of “Hold” and a consensus price target of $44.95.
Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Saturday, November 7th. The medical research company reported $0.42 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.11. The business had revenue of $511.40 million during the quarter, compared to the consensus estimate of $485.25 million. Bruker had a return on equity of 21.78% and a net margin of 8.04%. The business’s quarterly revenue was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.43 EPS. Research analysts anticipate that Bruker Co. will post 1.32 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, December 18th. Shareholders of record on Tuesday, December 1st will be paid a dividend of $0.04 per share. The ex-dividend date of this dividend is Monday, November 30th. This represents a $0.16 dividend on an annualized basis and a dividend yield of 0.31%. Bruker’s dividend payout ratio is currently 10.19%.
In other Bruker news, Director Cynthia M. Friend sold 800 shares of the business’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $37.58, for a total transaction of $30,064.00. Following the completion of the sale, the director now directly owns 12,657 shares in the company, valued at approximately $475,650.06. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 26.80% of the company’s stock.
Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the Bruker Scientific Instruments (BSI), and Bruker Energy and Supercon Technologies (BEST) segments.
Further Reading: What is a dead cat bounce?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.